Wadley, Antonia http://orcid.org/0000-0001-5654-0047
Kamerman, Peter
Pincus, Tamar
Evangeli, Michael
Chinaka, Tapiwa
Francois Venter, W. D.
Akpomiemie, Godspower
Moorhouse, Michelle
Parker, Romy
Funding for this research was provided by:
South African Medical Research Council
Medical Faculty Research Endowment Fund of the University of the Witwatersrand
Article History
Accepted: 6 November 2022
First Online: 27 November 2022
Declarations
:
: Antonia Wadley, Peter Kamerman, Tamar Pincus, Michael Evangeli, Tapiwa Chinaka, Michelle Moorhouse and Romy Parker declare that they have no competing interests. Venter’s unit receives funding from the Bill and Melinda Gates Foundation, SA Medical Research Council, National Institutes for Health, AIDS Fonds, Unitaid, Foundation for Innovative New Diagnostics and the Children's Investment Fund Foundation, has recently received funding from USAID, and receives drug donations from ViiV Healthcare, Merck, J&J and Gilead Sciences for investigator-led clinical studies. The unit does investigator-led studies with Merck and ViiV providing financial support and is doing commercial drug studies for Merck. The unit performs evaluations of diagnostic devices for multiple biotech companies. Individually, he receives honoraria for educational talks and advisory board membership for Gilead, ViiV, Mylan, Merck, Adcock-Ingram, Aspen, Abbott, Roche, J&J, Sanofi and Virology Education.
: The study received ethical clearance from the Human Research Ethics Committee (Medical) of the University of the Witwatersrand (Clearance No: M170560) and the study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki.
: Informed consent was obtained from all individual participants included in the study.